表紙
市場調査レポート

ワクチン市場の概要:病気の終わり

Vaccines: The End of Illness

発行 Insight Pharma Reports 商品コード 298556
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
ワクチン市場の概要:病気の終わり Vaccines: The End of Illness
出版日: 2014年11月30日 ページ情報: 英文 164 Pages
概要

当レポートでは、ワクチン市場について調査し、ワクチンの歴史、現況および技術の分析を提供しており、主要企業のプロファイル、ワクチンの将来の方向性、および専門家への調査インタビューなどをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 多くのワクチン技術

  • ワクチン生産:タマゴ vs.細胞培養
  • 細胞株のオプション
  • 従来型ワクチン
  • アジュバント
  • ナノ粒子ベースのワクチン
  • DNAワクチン
  • ワクチンが促進するT細胞活性化
  • 樹木状細胞

第3章 ワクチンの標的

  • 感染症
  • 癌ワクチン

第4章 大手製薬企業のワクチン

  • AstraZenica (Medimmune)
  • Baxter
  • GSK
  • J&J (Crucel)
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

第5章 小規模製薬企業のワクチン

第6章 規制の課題

  • 困難な道のり
  • 現在の規制状況

第7章 将来のワクチン技術

  • デリバリー・ストレージにおける課題
  • 乾燥ワクチン技術:
  • ピーク時への備え?
  • 万能ワクチン
  • バイオテロリズム:世界的な脅威?
  • 知的財産の均衡
  • ワクチンの明るい未来

第8章 ワクチン技術に関する意見の調査:業界メンバーによる

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

New to Insight Pharma Reports is Vaccines: The End of Illness. This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.

Specific Highlights Include:

  • This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies - including 35 small pharma companies and 8 big pharma companies profiled
  • The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
  • An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
  • Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer's disease and Parkinson's disease.
  • Survey of industry experts concerning the political economic and technological future of vaccine technology.
  • Over 20 pages of pipeline and clinical trial data specific to vaccine targets
  • Over 30 pages of pipeline and clinical trial data specific to cancer vaccines

Table of Contents

Executive Summary

CHAPTER 1 Introduction

  • 1.1 The History of Vaccination
    • 1.1.1 Ancient
    • 1.1.2 18th Century
    • 1.1.3 19th Century
    • 1.1.3.1 Koch and Pasteur
    • 1.1.3.2 Coley's Toxins
    • 1.1.4 Mid 20th Century
  • 1.2 Vaccines in the Doldrums: Late 20th century
    • 1.2.1 Liability Issues
    • 1.2.2 Vaccine Denialism
  • 1.3 The Current State of Vaccine Technology, 2014
    • 1.3.1 WHO
    • 1.3.2 Behemoth Players: Bill and Melinda Gates Foundation
    • 1.3.3 Big Pharma Jumps In

CHAPTER 2 A Cornucopia of Vaccine Technologies

  • 2.1 Viral Vaccine Production: Eggs Versus Cell Culture
  • 2.2 Cell Line Options
  • 2.3 Conventional Vaccines
  • 2.4 Adjuvants
  • 2.5 Nanoparticles-Based Vaccines
  • 2.6 DNA Vaccines
  • 2.7 Vaccines Driving T-Cell Activation
  • 2.8 Dendritic Cells

CHAPTER 3 Vaccine Targets

  • 3.1 Intectious Diseases
    • 3.1.1 Influenza
    • 3.1.2 Herpes Simplex
    • 3.1.3 C. Difficile
    • 3.1.4 HIV
    • 5.1.5 Pneumococcal Pneumonia
    • 3.1.6 Typhoid
    • 3.1.7 Candida
    • 3.1.8 Rabies
    • 3.1.9 Rptavoris
    • 3.1.10 Polio
    • 3.1.11 Malaria
    • 3.1.12 Other Parasitic Diseases
    • 3.1.13 Smallpox
    • 3.1.14 Cholera
    • 3.1.15 Mumps
    • 3.1.16 Diphtheria
  • 3.2 Cancer Vaccines
    • 3.2.1 Human Papilloma Virus
    • 3.2.2 Breast Cancer
    • 3.2.3 Pancreatic Cancer
    • 3.2.4 Renal Cell Carcinoma
    • 3.2.5 Melanoma: Dendritic Cells
    • 3.2.6 Prostate Cancer

CHAPTER 4 Big Pharma Vaccinology

  • 4.1 AstraZeneca (Medimmune)
  • 4.2 Baxter
  • 4.3 GSDK Pharma4.4
  • 4.4 J&J (Crucell)
  • 4.5 Merck
  • 4.6 Novartis
  • 4.7 Pfizer
  • 4.8 Sanofi

CHAPTER 5 Small Pharma Vaccines

  • 5.1 AC Immune
  • 5.2 Aeras
  • 5.3 AlphaVax
  • 5.5 Asthellas Pharma Inc.
  • 5.6 Bavarian Nordic
  • 5.7 BiondVax Pharmaceuticals
  • 5.8 Brassch Biotech LLC
  • 5.9 Celldex Therapeutics
  • 5.10 ChronTech Pharma
  • 5.11 Emergent BioSolution Inc
  • 5.12 EpiVax
  • 5.13 GenVec
  • 5.14 GeoVax
  • 5.15 Genocia Biosclences
  • 5.16 Immune Targeting Systems
  • 5.17 Indian Immunologicals Limited
  • 5.18 Inovio
  • 5.19 Inviragen
  • 5.20 Juvaris Biotherapeutics
  • 5.21 Medicago
  • 5.22 Mymetics Corporation
  • 5.23 NovaRx
  • 5.24 Novavax, Inc.
  • 5.25 Nuron
  • 5.26 OPKO Health
  • 5.27 Profectus Biosclence Inc
  • 5.28 SinovacBiotech Ltd
  • 5.29 Sorrento Therapeutics, Inc.
  • 5.30 Tapimmune
  • 5.31 Valneva
  • 5.32 Vaxinnate
  • 5.33 VaxLiant
  • 5.34 VBI Vaccines
  • 5.35 Vical

CHAPTER 6 Regulatory Issues

  • 6.1 A Bumpy Road
  • 6.2 Current Regulatory Status

CHAPTER 7 The Future of Vaccine Technology

  • 7.1 Challenges In Delivery And Storage
  • 7.2 Dry Vaccine Technology: Ready For Prime Time
  • 7.3 A Universal Vaccine
  • 7.4 Outlandish Targets
    • 7.4.1 Drug Abuse
    • 7.4.2 Obesity
    • 7.4.3 Smoking
    • 7.4.4 Alcoholism
    • 7.4.5 Alzheimer's Disease
    • 7.4.6 Parkinson's Disease
  • 7.5 Bioterrorism: A Global Threat
  • 7.6 Intellectual Property in the Balance
  • 7.7 A bright Future For Vaccines

CHAPTER 8 Survey of Opinion Concerning Vaccine Technology by Members of the Industry

About Cambridge Healthtech Institute

FIGURES

    Figure 1.1: Overall Decline in Worldwide Death Rates
  • Figure 2.5: Application of Nano-Sized Delivery Systems
  • Figure 5.11: Emergent's ADAPTIR Design Technology for Antibody Therapeutics
  • Figure 5.15: Genocea Technology for Screening Candidate Vaccines Components
  • Figure 6.2: Development of Anti-cancer Vaccine Products and the Regulatory Guidance Throughout the Process
  • Figure 8.1: Makeup of the Participants in the Survey
  • Figure 8.2: Breakdown of Opinions of the Industrial Commitment of Resources
  • Figure 8.3: How Should the Industry Focus its R&D Efforts in Vaccine Technology?
  • Figure 8.4: What are the Most Promising Cancer Vaccine Targets?
  • Figure 8.5: How Seriously are the Federal Governmental Bodies Committed to Vaccine Technology?
  • Figure 8.6: State and Local Governmental Support for R&D. How Does it Stack Up?
  • Figure 8.7: The Softest Cancer Vaccine Target
  • Figure 8.8: Where is Bioprocessing of Vaccines Headed?
  • Figure 8.9: Why Would a Vaccine Development Program be Vetoed?
  • Figure 8.10: The Fallout from Vaccine Denialism
  • Figure 8.11: Where is Bioprocessing of Vaccines Headed?
  • Figure 8.12: Cancer Vaccines: Still a Long Ways Off
  • Figure 8.13: AIDS Vaccines: Further Down the Road than Cancer Vaccines?
  • Figure 8.14: The Road Ahead: Daunting Challenges
  • Figure 8.15: Is Regulatory Control of Vaccines a Problem?
  • Figure 8.16: How Does the Industry Feel About Vaccines as a Barrier to Terroristic Threats?
  • Figure 8.17: When Vaccines Fail
  • Figure 8.18: Bioinformatics: A Pathway to Innovative Vaccine Antigens
  • Figure 8.19: Counteracting Vaccine Denialism
  • Figure 8.20: Opinions on the Rise of Therapeutic Vaccines
  • Figure 8.21: The Future of Oral Vaccines
  • Figure 8.22: Vaccine Technology in the Third World
  • Figure 8.23: Vaccines and the Battle Against Hepatitis C
  • Figure 8.24: Academic/Industrial Partnerships: Do They Have a Future?
  • Figure 8.25: Alternative Pathways Toward Speeding Vaccine Development
  • Figure 8.26: A New Look at DNY Vaccines

TABLES

    Table 2.2: Anti-Viral Vero Cell-Based Vaccines
  • Table 3.1: Vaccines: Clinical Trials and Pipeline Data
  • Table 3.2: Cancer Vaccines: Clinical Trials and Pipeline Data

Back to Top